M1FG
UBX

Mach-1 Financial Group’s Unity Biotechnology UBX Stock Holding History

Mach-1 Financial Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed – – 440
2022
Q3 		$0 Hold
50
– – ﹤0.01% 435
2022
Q2 		$0 Hold
50
– – ﹤0.01% 440
2022
Q1 		$0 Hold
50
– – ﹤0.01% 313
2021
Q4 		$0 Buy
+50
New +$1.09K ﹤0.01% 298

Other funds holding UBX

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mach-1 Financial Group's UBX Position: Q4 2022 in Review

Mach-1 Financial Group sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 50 shares.

Mach-1 Financial Group first reported a position in UBX in Q4 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

  • Mach-1 Financial Group reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Mach-1 Financial Group sold 50 Unity Biotechnology shares in Q4 2022.
  • Mach-1 Financial Group first reported a position in Unity Biotechnology in Q4 2021 and held it in 4 quarters.
  • Mach-1 Financial Group's Unity Biotechnology position peaked at $0 in Q3 2022.
  • 54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Mach-1 Financial Group's 13F filing for Q4 2022, filed 2 Feb 2023.